FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031489542> ?p ?o ?g. }

• W2031489542 endingPage "241" @default.
• W2031489542 startingPage "235" @default.
• W2031489542 abstract "Purpose Little is known about outcomes in the use of third-line chemotherapy in cases of advanced gastric cancer (AGC). The primary aim of this retrospective study was to evaluate outcomes of docetaxel-based chemotherapy in patients with AGC that progressed after both oxaliplatin-based and irinotecan-based regimens. Materials and Methods Eligible patients were those with AGC who had previous chemotherapy including fluoropyrimidine and oxaliplatin as well as fluoropyrimidine and irinotecan and who received subsequent docetaxel-based chemotherapy. Thirty-five patients were retrospectively recruited from 5 medical centers in Korea. Patients received either weekly or 3 weekly with docetaxel +/- cisplatin. Results Thirty-one out of 35 patients were evaluated for treatment response. A total of 94 cycles of chemotherapy (median, 2; range, 1 to 7) were administered. The overall response rate was 14.3%, and the disease control rate was 45.7%. The median progression-free survival (PFS) was 1.9 months (95% confidence interval [CI], 1.1 to 2.7 months). The median overall survival (OS) was 3.6 months (95% CI, 2.8 to 4.4 months). PFS and OS were significantly prolonged in patients of the Eastern Cooperative Oncology Group, with performance status of 0 or 1 in multivariate analysis (PFS: hazard ratio[HR], 0.411; 95% CI, 0.195 to 0.868; p=0.020 and OS: HR, 0.390; 95% CI, 0.184 to 0.826; p=0.014, respectively). Four of the 35 patients enrolled in the study died due to infection associated with neutropenia. Conclusion Our findings suggest that salvage docetaxel-based chemotherapy is a feasible treatment option for AGC patients with good performance status (PS), whereas chemotherapy for patients with poor PS (PS≤2) should be undertaken with caution for those who previously failed oxaliplatin- and irinotecan-based regimens. Key words: Stomach neoplasms, Docetaxel, Oxaliplatin, Irinotecan" @default.
• W2031489542 created "2016-06-24" @default.
• W2031489542 creator A5003029657 @default.
• W2031489542 creator A5011928803 @default.
• W2031489542 creator A5012507797 @default.
• W2031489542 creator A5024408158 @default.
• W2031489542 creator A5026351538 @default.
• W2031489542 creator A5045192289 @default.
• W2031489542 creator A5057146015 @default.
• W2031489542 creator A5060913021 @default.
• W2031489542 creator A5068310127 @default.
• W2031489542 creator A5085086203 @default.
• W2031489542 date "2012-12-31" @default.
• W2031489542 modified "2023-10-07" @default.
• W2031489542 title "Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies" @default.
• W2031489542 cites W1968659207 @default.
• W2031489542 cites W1978679862 @default.
• W2031489542 cites W1984322631 @default.
• W2031489542 cites W1992408996 @default.
• W2031489542 cites W1995622300 @default.
• W2031489542 cites W2019607817 @default.
• W2031489542 cites W2034162342 @default.
• W2031489542 cites W2046432359 @default.
• W2031489542 cites W2068688816 @default.
• W2031489542 cites W2075467821 @default.
• W2031489542 cites W2102880631 @default.
• W2031489542 cites W2106787323 @default.
• W2031489542 cites W2114734455 @default.
• W2031489542 cites W2130522735 @default.
• W2031489542 cites W2131463911 @default.
• W2031489542 cites W2145390243 @default.
• W2031489542 cites W2157416388 @default.
• W2031489542 cites W2160555312 @default.
• W2031489542 cites W2315009998 @default.
• W2031489542 cites W2945113760 @default.
• W2031489542 cites W4210975948 @default.
• W2031489542 doi "https://doi.org/10.4143/crt.2012.44.4.235" @default.
• W2031489542 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3546270" @default.
• W2031489542 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23341787" @default.
• W2031489542 hasPublicationYear "2012" @default.
• W2031489542 type Work @default.
• W2031489542 sameAs 2031489542 @default.
• W2031489542 citedByCount "24" @default.
• W2031489542 countsByYear W20314895422013 @default.
• W2031489542 countsByYear W20314895422014 @default.
• W2031489542 countsByYear W20314895422015 @default.
• W2031489542 countsByYear W20314895422016 @default.
• W2031489542 countsByYear W20314895422017 @default.
• W2031489542 countsByYear W20314895422018 @default.
• W2031489542 countsByYear W20314895422019 @default.
• W2031489542 countsByYear W20314895422021 @default.
• W2031489542 countsByYear W20314895422022 @default.
• W2031489542 countsByYear W20314895422023 @default.
• W2031489542 crossrefType "journal-article" @default.
• W2031489542 hasAuthorship W2031489542A5003029657 @default.
• W2031489542 hasAuthorship W2031489542A5011928803 @default.
• W2031489542 hasAuthorship W2031489542A5012507797 @default.
• W2031489542 hasAuthorship W2031489542A5024408158 @default.
• W2031489542 hasAuthorship W2031489542A5026351538 @default.
• W2031489542 hasAuthorship W2031489542A5045192289 @default.
• W2031489542 hasAuthorship W2031489542A5057146015 @default.
• W2031489542 hasAuthorship W2031489542A5060913021 @default.
• W2031489542 hasAuthorship W2031489542A5068310127 @default.
• W2031489542 hasAuthorship W2031489542A5085086203 @default.
• W2031489542 hasBestOaLocation W20314895421 @default.
• W2031489542 hasConcept C121608353 @default.
• W2031489542 hasConcept C126322002 @default.
• W2031489542 hasConcept C143998085 @default.
• W2031489542 hasConcept C167135981 @default.
• W2031489542 hasConcept C207103383 @default.
• W2031489542 hasConcept C2776694085 @default.
• W2031489542 hasConcept C2777063308 @default.
• W2031489542 hasConcept C2780259306 @default.
• W2031489542 hasConcept C2780962732 @default.
• W2031489542 hasConcept C2781190966 @default.
• W2031489542 hasConcept C44249647 @default.
• W2031489542 hasConcept C526805850 @default.
• W2031489542 hasConcept C71924100 @default.
• W2031489542 hasConceptScore W2031489542C121608353 @default.
• W2031489542 hasConceptScore W2031489542C126322002 @default.
• W2031489542 hasConceptScore W2031489542C143998085 @default.
• W2031489542 hasConceptScore W2031489542C167135981 @default.
• W2031489542 hasConceptScore W2031489542C207103383 @default.
• W2031489542 hasConceptScore W2031489542C2776694085 @default.
• W2031489542 hasConceptScore W2031489542C2777063308 @default.
• W2031489542 hasConceptScore W2031489542C2780259306 @default.
• W2031489542 hasConceptScore W2031489542C2780962732 @default.
• W2031489542 hasConceptScore W2031489542C2781190966 @default.
• W2031489542 hasConceptScore W2031489542C44249647 @default.
• W2031489542 hasConceptScore W2031489542C526805850 @default.
• W2031489542 hasConceptScore W2031489542C71924100 @default.
• W2031489542 hasIssue "4" @default.
• W2031489542 hasLocation W20314895421 @default.
• W2031489542 hasLocation W20314895422 @default.
• W2031489542 hasLocation W20314895423 @default.
• W2031489542 hasLocation W20314895424 @default.
• W2031489542 hasOpenAccess W2031489542 @default.
• W2031489542 hasPrimaryLocation W20314895421 @default.

• next